Depomed
Dec 07, 2017
December 7 Business Cocktail
AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
